CORT News and Press, Corcept Therapeutics Incorporated

2024-07-16 11:50:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. With large-cap valuati...

2024-06-26 06:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips I’m on the hunt for ‘Strong Buy’ biotech stocks . According to Finviz.com, there are 680 U.S.-listed biotech stocks. Of those, 73 have a market capitalization o...

Results from the CATALYST clinical trial were presented at the American Diabetes Association’s 84 th Scientific Sessions at a featured plenary session titled: “Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes” With 1,055 patients enro...

2024-06-14 09:55:20 ET More on Corcept Therapeutics, Teva, etc. Corcept Therapeutics Stock Merits Accumulation Teva Pharmaceutical Industries Limited (TEVA) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Teva Pharmaceutical: Buy This Bargain Befo...

2024-06-12 10:00:07 ET Edward Nash from Canaccord Genuity issued a price target of $38.00 for CORT on 2024-06-12 07:45:00. The adjusted price target was set to $38.00. At the time of the announcement, CORT was trading at $32.79. The overall price target consensus is at $...

2024-06-11 12:08:45 ET Summary Corcept Therapeutics Incorporated share prices were initially suppressed after a court ruling that Teva's generic version of Korlym would not infringe on its patents. However, the company is preparing an NDA for Korlym's successor, which could be app...

Shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) traded at a new 52-week high today and are currently trading at $34.06. So far today, approximately 79,094 shares have been exchanged, as compared to an average 30-day volume of 1.09M shares. Corcept Therapeutics Incorporated discover...

MENLO PARK, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the...

2024-05-28 08:33:51 ET More on Corcept Therapeutics Corcept Therapeutics Incorporated (CORT) Q1 2024 Earnings Call Transcript Corcept Therapeutics Q1 2024 Earnings Preview Corcept falls after phase 3 results on Cushing's candidate doesn't include some data Se...

MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the...